• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Medical society backs drug-eluting sinus implants

September 19, 2016 By Sarah Faulkner

American Rhinologic SocietyThe American Rhinologic Society today endorsed the use of drug-eluting implants in sinus cavities for patients following surgery.

A successful sinus surgery depends on proper healing and avoiding inflammation, the society said in a press release. Drug-eluting implants can reduce nasal polyps and inflammation, which can decrease a patient’s use of oral medication, according to the society.

“The American Rhinologic Society thus feels strongly that drug-eluting implants are not investigational and should be available to our patients, when selected by the physician, in order to maximize outcomes,” the report concluded.

Intersect ENT‘s (NSDQ:XENT) Propel and Propel mini are the first and only steroid-releasing implants approved by the FDA to maintain open passages created in surgery, according to the company.

“We are pleased that the ARS has issued this clear statement for its members endorsing the use of drug eluting sinus implants,” president & CEO Lisa Earnhardt said in prepared remarks. “Our Propel steroid-releasing implants, the first and only FDA-approved products of their kind, have been proven to deliver improved outcomes clinically and economically. To date, more than 100,000 patients have been treated with Propel and we will continue to work diligently with payers and providers to ensure patients and physicians have access to this technology. In addition, we look forward to continuing to provide innovative solutions for the ENT specialty.”

The statement comes just weeks after Intersect announced that CareFirst BlueCross BlueShield issued a positive coverage decision for its steroid-releasing sinus implants.

An analysis published in the Journal of Medical Economics showed the use of Intersect’s implants following endoscopic sinus surgery is expected to have a negligible impact on the healthcare budget of a commercial payer or a self-funded employer with 1.5 million covered beneficiaries.

CareFirst serves 3.2 million people across Maryland, D.C., and Northern Virginia.

Filed Under: Drug-Device Combinations, Featured, Otolaryngology Ear, Nose & Throat Tagged With: American Rhinologic Society, Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS